Step 1 topics → Cardiovascular → Vasopressors and Inotropes

Vasopressors and Inotropes

USMLE Step 1 trap: Selects dopamine over norepinephrine as first-line for septic shock based on a misconception about renal-dose dopamine benefit. Norepinephrine is the first-line vasopressor for septic shock; dopamine is associated with higher rates of arrhythmia and increased mortality compared to norepinephrine in this setting.

Vasopressors and inotropes are a high-yield pharmacology topic because the USMLE Step 1 doesn't just ask you to name the drugs — it asks you to match the right agent to the right shock physiology. The core distinction is this: vasopressors raise blood pressure by increasing vascular resistance (e.g., norepinephrine, vasopressin), while inotropes improve cardiac output by increasing contractility (e.g., dobutamine, milrinone). Some agents do both. The exam exploits the fact that the wrong drug in the wrong shock type makes outcomes worse, not better.

The trickiest part of this topic is that students often apply a one-size-fits-all approach to shock management. Norepinephrine is first-line for septic and distributive shock — but in cardiogenic shock, increasing afterload with a pure vasopressor can kill the patient. You need inotropy. Similarly, the 'renal-dose dopamine' myth is a classic Step 1 trap: dopamine is not first-line for septic shock and does not have proven renal-protective benefits; norepinephrine has better outcomes data. If the vignette shows septic shock and asks for the best vasopressor, the answer is norepinephrine, not dopamine.

The dobutamine vs. milrinone distinction is another angle the USMLE Step 1 loves. Both increase cAMP in cardiomyocytes and both are used in acute decompensated heart failure or cardiogenic shock — but their mechanisms are different, and that difference matters clinically (especially in patients on beta-blockers, where dobutamine loses effectiveness but milrinone does not). Nail the mechanism, nail the clinical scenario, and this topic becomes straightforward.

From real student decks
85%have cards covering this topic
69%have mature cards

Common misconceptions

Common mistake
Wrong: Dopamine is the first-line vasopressor for septic shock because it increases renal perfusion.
Right: Norepinephrine is the first-line vasopressor for septic shock; dopamine is associated with higher rates of arrhythmia and increased mortality compared to norepinephrine in this setting.
The 'renal-dose dopamine' concept has been debunked — dopamine does not meaningfully protect the kidneys in septic shock and is associated with more arrhythmias and higher mortality compared to norepinephrine. Norepinephrine is the first-line vasopressor for septic shock because it reliably increases systemic vascular resistance without the arrhythmia burden. When you see a septic shock vignette asking for the best vasopressor, default to norepinephrine.
Common mistake
Wrong: Dobutamine and milrinone both increase cardiac contractility by the same mechanism (beta-1 agonism).
Right: Dobutamine is a beta-1 agonist that increases cAMP via receptor activation, while milrinone is a phosphodiesterase-3 inhibitor that increases cAMP by preventing its breakdown — both raise cAMP but through distinct mechanisms.
Dobutamine is a direct beta-1 adrenergic agonist — it binds the receptor, activates adenylyl cyclase, and generates more cAMP. Milrinone works entirely downstream: it inhibits phosphodiesterase-3, the enzyme that degrades cAMP, so cAMP accumulates without any receptor activation. This means milrinone retains effectiveness even when beta-receptors are downregulated or blocked (e.g., in a patient on carvedilol), while dobutamine would not. Same end result (more cAMP, more contractility), completely different entry point.
Common mistake
Wrong: Norepinephrine is the preferred agent in cardiogenic shock because it raises blood pressure.
Right: Dobutamine (or milrinone) is preferred in cardiogenic shock to improve cardiac output; norepinephrine increases afterload and can worsen pump failure, though it may be added if hypotension is refractory.
In cardiogenic shock, the problem is a failing pump — cardiac output is low, not vascular tone. Giving norepinephrine increases afterload (the resistance the heart pumps against), which worsens pump function in an already-struggling ventricle. Dobutamine or milrinone are the correct agents here because they directly increase contractility and improve forward flow. Norepinephrine may be added later if blood pressure remains dangerously low despite inotropy, but it is not the first move.
Guided session

Stuck on this? An AI tutor that probes your understanding and catches where your reasoning breaks.

Start a session →
Free Deck audit

Already run Anki? See if your deck covers this topic.

Upload your deck →

What the exam tests

  1. Given a clinical scenario describing a specific type of shock (septic, cardiogenic, neurogenic, etc.), identify the correct first-line vasoactive agent and explain why it fits that shock physiology.
  2. Distinguish between dobutamine and milrinone at the mechanistic level — specifically, recognize that dobutamine activates beta-1 receptors to increase cAMP production, while milrinone inhibits PDE-3 to prevent cAMP breakdown, and know when each is preferred.

Can you avoid these mistakes?

A 68-year-old man presents with hypotension, warm skin, fever, and a lactate of 4.2 mmol/L after a UTI. He is fluid-resuscitated but remains hypotensive. Which vasoactive agent is first-line, and why not dopamine?
A 55-year-old woman with ischemic cardiomyopathy is admitted with acute decompensated heart failure and a cardiac index of 1.6 L/min/m². She is on carvedilol at home. Between dobutamine and milrinone, which is more likely to be effective given her medication, and what is the mechanistic reason?
A patient in cardiogenic shock is receiving both dobutamine and milrinone. An attending asks you to explain what these two drugs share mechanistically and how each achieves it through a different entry point. Walk through the answer.
A patient in cardiogenic shock has a systolic BP of 70 mmHg despite dobutamine infusion. A colleague suggests adding norepinephrine. What is the theoretical concern with this, and under what circumstance would it still be appropriate?

Related topics

Adrenergic Receptors and Agonists Shock Classification and Recognition Capillary Fluid Exchange (Starling Forces and Edema) Heart Development and Looping Cardiac Septation Fetal Circulation and Transition

Find out what you actually understand about this topic — a tutor that probes your reasoning and catches where it breaks.

Start a session →

Already run Anki? Get a free deck audit →